Zinc metabolism during therapy with inhibitors of angiotensin converting enzyme;WPLYW INHIBITOROW ENZYMU PRZEKSZTALCAJACEGO ANGIOTENSYNE I NA WYBRANE PARAMETERY GOSPODARKI CYNKOWEJ

Polskie Archiwum Medycyny Wewnetrznej

Volumn 96, Issue 1, 1996, Pages 32-38

  Pȩczkowska, Mariola ^a,b  

^a Klinika Kardiochirurgii Instytutu Kardiologii AM   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Benazepril; Captopril; Skin changes; Taste and smell disorders; Zinc

Indexed keywords

BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BENZAZEPINE DERIVATIVE; ZINC;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; ZINC METABOLISM; BLOOD; DRUG ADMINISTRATION; HYPERTENSION; MIDDLE AGED;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CAPTOPRIL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; ZINC;

EID: 0030184211     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mrozikiewicz A.: Objawy niepoża̧dane. Leki hamuja̧ce enzym przekształcaja̧cy angiotensynȩ: działanie i zastosowanic kliniczne Pod redakcja̧ prof, H. Adamskiej-Dyniewskiej. Towarzystwo Terapii Monitorowanej, 1992, 114.
2. Opte L.: ACE inhibitors: Side effects and contraindications. Angiotensin Converting Enzyme Inhibitors. Scientific basis for clinical use. Wiley-Liss, 1992, 194.
3. Seelig M.S.: Auto-immune complications of D-penicillamine. A possible result of zinc and magnesium depletion and of pyridoxine inactivation. J.Am. Coll. Nutr., 1982, 207.
4. Zumkley H., Bertram H.P., Vetter H., Zidek W., Lasse H., Zinc metabolism during captopril treatment. Horm. Metab. Res., 1985, 17, 256.
5. Brzozowski R., łazicka-Frelek M., Marcinkowska-Suchowierska E. i wsp.: Niektóre zagadnienia zwiazane z gospodarka̧. cynkiem w ustroju. Pol. Arch. Med. Wewn., 1988, 80, 162.
6. Prasad A.S.: Clinical, endocrynological and biochemical effects of zinc deficiency. Clin. Endocrynol. Metab., 1985, 14, 567.
7. Saltman P.: Trace elements and blood pressure. Ann. Intern. Med., 1983, 98, 823.
8. Vallee B.L., Falchuk K.H.: The biochemical basis of zinc physiology. Physiol. Rev., 1993, 73, 79.
9. Erdos E.G.: Angiotensin I converting enzyme and the changest in our concepts through the years. Hypertension, 1990, 16, 363.
10. Bunning P.: The catalytic mechanism of angiotensin converting enzyme. Clin. Exp. Hypertens., 1983, 5, 1263-1275.
11. Golik A., Averbuhk Z., Cohn M. i wsp.: Effect of diuretics on captopril-induced urine zinc excretion. Eur. J. Clin. Pharmacol., 1990, 38, 359.
12. Golik A., Modai D., Averbuks Z. i wsp.: Zinc metabolism in patients treated with captopril versus enalapril. Metabolism, 1990, 39, 665.
13. Neil-Dwyer G., Marus A.: ACE inhibitors in hypertension: assessment of taste smell function in clinical trials. J. Hum. Hypertens., 1989, 3, 1269.
14. Smit A.J., Hoorntje S.J., Danker A.J.M.: Zinc deficiency during captopril treatment. Nephron, 1983, 34, 196.
15. Edwards I.R., Coulter D.M., Beasley D.M.G., Macintosh D.: Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br. J. Clin. Pharmacol., 1987, 23, 529.